Not checkedNot checked for notices yet.
Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial
Mary Kathryn Dahlgren, Ashley M. Lambros, Rosemary T. Smith and 3 more
Communications Medicine · 2022
doi:10.1038/s43856-022-00202-8 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Dahlgren et al. conduct an open-label phase 2 trial of a full-spectrum, high-cannabidiol product in 14 patients with moderate-to-severe anxiety. Anxiety is significantly reduced and the drug well-tolerated with no serious adverse events.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.